Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

68 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Bortezomib Maintenance Therapy as a Standard of Care Provides Favorable Outcomes in Newly Diagnosed Myeloma Patients: A Multisite Real-Life Study.
Luttwak E, Gatt ME, Lebel E, Lavi N, Tadmor T, Natalia K, Benyamini N, Horowitz N, Geva M, Suriu C, Avivi I, Trestman S, Mittelman M, Rouvio O, Cohen YC. Luttwak E, et al. Clin Lymphoma Myeloma Leuk. 2020 Nov;20(11):e850-e857. doi: 10.1016/j.clml.2020.06.002. Epub 2020 Jun 11. Clin Lymphoma Myeloma Leuk. 2020. PMID: 32624446
Daratumumab for relapsed AL amyloidosis-When cumulative real-world data precedes clinical trials: A multisite study and systematic literature review.
Shragai T, Gatt M, Lavie N, Vaxman I, Tadmor T, Rouvio O, Zektser M, Horowitz N, Magen H, Ballan M, Suru C, Luttwak E, Levi S, Ziv-Baran T, Avivi I, Cohen YC. Shragai T, et al. Among authors: luttwak e. Eur J Haematol. 2021 Feb;106(2):184-195. doi: 10.1111/ejh.13535. Epub 2020 Nov 9. Eur J Haematol. 2021. PMID: 33090552
Identification of resistance pathways and therapeutic targets in relapsed multiple myeloma patients through single-cell sequencing.
Cohen YC, Zada M, Wang SY, Bornstein C, David E, Moshe A, Li B, Shlomi-Loubaton S, Gatt ME, Gur C, Lavi N, Ganzel C, Luttwak E, Chubar E, Rouvio O, Vaxman I, Pasvolsky O, Ballan M, Tadmor T, Nemets A, Jarchowcky-Dolberg O, Shvetz O, Laiba M, Shpilberg O, Dally N, Avivi I, Weiner A, Amit I. Cohen YC, et al. Among authors: luttwak e. Nat Med. 2021 Mar;27(3):491-503. doi: 10.1038/s41591-021-01232-w. Epub 2021 Feb 22. Nat Med. 2021. PMID: 33619369 Free PMC article.
Humoral response rate and predictors of response to BNT162b2 mRNA COVID19 vaccine in patients with multiple myeloma.
Avivi I, Balaban R, Shragai T, Sheffer G, Morales M, Aharon A, Lowenton-Spier N, Trestman S, Perry C, Benyamini N, Mittelman M, Tabib Y, Bar Lev T, Zavaro M, Herishanu Y, Luttwak E, Cohen YC. Avivi I, et al. Among authors: luttwak e. Br J Haematol. 2021 Oct;195(2):186-193. doi: 10.1111/bjh.17608. Epub 2021 Jul 1. Br J Haematol. 2021. PMID: 34196388 Free PMC article.
Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with B-cell non-Hodgkin lymphoma.
Perry C, Luttwak E, Balaban R, Shefer G, Morales MM, Aharon A, Tabib Y, Cohen YC, Benyamini N, Beyar-Katz O, Neaman M, Vitkon R, Keren-Khadmy N, Levin M, Herishanu Y, Avivi I. Perry C, et al. Among authors: luttwak e. Blood Adv. 2021 Aug 24;5(16):3053-3061. doi: 10.1182/bloodadvances.2021005094. Blood Adv. 2021. PMID: 34387648 Free PMC article.
68 results